What are the benefits of using metformin as a first-line therapy for T2DM?
Metformin has been shown to reduce HbA1c, weight, and improve ASCVD outcomes compared with sulfonylureas, as well as having an acceptable safety profile and low cost. It has also been demonstrated to reduce CVD events and CVD deaths in adults with T2DM and high ASCVD risk. However, it should be used with caution in patients with CKD due to a small risk of lactic acidosis.